VOR on Nasdaq

Vor Biopharma Inc.

Biological products company, listed on Nasdaq (VOR).

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with another stock.

TickerVOR on Nasdaq
IndustryBiological Products, (No Diagnostic Substances)
Business address500 Boylston Street, Suite 1350, Boston, Ma 02116²
Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income³⁴⁵⁶⁷-$371.6M in 2025+757% since 2020

Net income³⁴⁵⁶⁷-$696.0M in 2025+1506% since 2020

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁷

Period ending	2025-12-31	2024-12-31
Research and development	$321.5M	$93.3M
General and administrative	$50.1M	$27.9M
Total operating expenses	$371.6M	$121.2M
Loss from operations	-$371.6M	-$121.2M
Interest income	$5.9M	$4.3M
Other income	$4.2M	$0
Change in fair value of warrant liabilities	-$334.4M	$0
Total other income (expense), net	-$324.3M	$4.3M
Net loss	-$696.0M	-$116.9M
Net loss per share, basic	-$70.50	-$34.03
Net loss per share, diluted	-$70.50	-$34.03
Weighted-average common shares outstanding, basic	9.9M shares	3.4M shares
Weighted-average common shares outstanding, diluted	9.9M shares	3.4M shares
Unrealized gain on available for sale marketable securities	$19.0K	$99.0K
Total other comprehensive income	$19.0K	$99.0K
Comprehensive loss	-$696.0M	-$116.8M

Total assets³⁴⁵⁶⁷$464.1M in 2025+511% since 2020

Total liabilities³⁴⁵⁶⁷$628.4M in 2025+2174% since 2020

Shareholders’ equity³⁴⁵⁶⁷-$164.3M in 2025+843% since 2019

Cash³⁴⁵⁶⁷$396.5M in 2025+717% since 2020

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$396.5M	$81.9M
Marketable securities	$58.7M	$10.0M
Prepaid expenses	$1.2M	$4.2M
Other current assets	$1.7M	$380.0K
Total current assets	$458.1M	$96.5M
Restricted cash equivalents	$168.0K	$2.4M
Property and equipment, net	$533.0K	$6.6M
Operating lease right-of-use assets	$2.9M	$35.0M
Other assets	$2.4M	$2.4M
Total assets	$464.1M	$142.9M
Accounts payable	$5.1M	$1.5M
Accrued liabilities	$19.8M	$12.9M
Operating lease liabilities	$280.0K	$4.2M
Total current liabilities	$25.2M	$18.6M
Operating lease liabilitiesnon-current	$2.7M	$27.6M
Warrant liabilities	$600.5M	$0
Total liabilities	$628.4M	$46.2M
Common stock, $0.0001 par value; 800,000,000 and 400,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 38,720,196 and 6,238,799 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	$18.0K	$13.0K
Additional paid-in capital	$988.6M	$553.6M
Accumulated other comprehensive income	$41.0K	$22.0K
Accumulated deficit	-$1.2B	-$457.0M
Total stockholders' equity (deficit)	-$164.3M	$96.7M	$150.7M
Total liabilities and stockholders' equity (deficit)	$464.1M	$142.9M
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10.0M shares	10.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	800.0M shares	400.0M shares
Common stock, shares issued	38.7M shares	6.2M shares
Common stock, shares outstanding	38.7M shares	6.2M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$396.5M	$81.9M
Marketable securities	$58.7M	$10.0M
Prepaid expenses	$1.2M	$4.2M
Other current assets	$1.7M	$380.0K
Total current assets	$458.1M	$96.5M
Restricted cash equivalents	$168.0K	$2.4M
Property and equipment, net	$533.0K	$6.6M
Operating lease right-of-use assets	$2.9M	$35.0M
Other assets	$2.4M	$2.4M
Total assets	$464.1M	$142.9M
Accounts payable	$5.1M	$1.5M
Accrued liabilities	$19.8M	$12.9M
Operating lease liabilities	$280.0K	$4.2M
Total current liabilities	$25.2M	$18.6M
Operating lease liabilitiesnon-current	$2.7M	$27.6M
Warrant liabilities	$600.5M	$0
Total liabilities	$628.4M	$46.2M
Common stock, $0.0001 par value; 800,000,000 and 400,000,000 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 38,720,196 and 6,238,799 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively	$18.0K	$13.0K
Additional paid-in capital	$988.6M	$553.6M
Accumulated other comprehensive income	$41.0K	$22.0K
Accumulated deficit	-$1.2B	-$457.0M
Total stockholders' equity (deficit)	-$164.3M	$96.7M	$150.7M
Total liabilities and stockholders' equity (deficit)	$464.1M	$142.9M
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	10.0M shares	10.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	800.0M shares	400.0M shares
Common stock, shares issued	38.7M shares	6.2M shares
Common stock, shares outstanding	38.7M shares	6.2M shares

Cash from operations³⁴⁵⁶⁷-$142.7M in 2025+293% since 2020

Capital spending³⁴⁵⁶⁷$941.0K in 2025−77% since 2020

Free cash flow³⁴⁵⁶⁷-$143.7M in 2025+255% since 2020

Dividends paid³⁴⁵⁶⁷$0 in 2025

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁷

Period ending	2025-12-31	2024-12-31
Net loss	-$696.0M	-$116.9M
Depreciation expense	$2.9M	$3.5M
Non-cash lease expense	$5.6M	$5.0M
Stock-based compensation	$18.9M	$9.8M
Transaction costs for issuance of pre-funded warrants	$643.0K	$0
Change in fair value of warrant liabilities	$334.4M	$0
Interest amortization on marketable securities	-$67.0K	-$1.1M
Loss (gain) on sale of property and equipment	$3.3M	-$18.0K
Issuance of pre-funded warrants in connection with the acquisition of in-process research and development	$177.4M	$0
Operating lease liabilities	-$2.4M	-$3.8M
Prepaid expenses and other current assets	$1.7M	-$835.0K
Accounts payable and accrued liabilities	$10.9M	$2.2M
Other assets	$0	$2.4M
Net cash used in operating activities	-$142.7M	-$99.7M
Purchases of marketable securities	-$53.7M	-$9.9M
Proceeds from maturities of marketable securities	$5.0M	$107.0M
Purchases of property and equipment	-$941.0K	-$229.0K
Proceeds from sales of property and equipment	$799.0K	$0
Net cash (used in) provided by investing activities	-$48.8M	$96.9M
Proceeds from the issuance of common stock from private placement	$150.0M	$55.5M
Proceeds from the issuance of common stock from underwritten public offering, net of underwriting discount and commissions	$108.1M	$0
Proceeds from the issuance of pre-funded warrants	$175.0M	$0
Payment of issuance costs related to underwritten public offering and private placements	-$1.3M	-$2.3M
Proceeds from the issuance of common stock from at-the-market sales agreement, net of issuance costs	$70.1M	$275.0K
Withholding of shares for tax withholdings upon vesting of restricted stock unit awards	-$254.0K	-$333.0K
Proceeds from stock option exercises and the issuance of shares under ESPP	$2.2M	$225.0K
Net cash provided by financing activities	$503.8M	$53.4M
Net increase in cash, cash equivalents and restricted cash equivalents	$312.3M	$50.6M
Right-of-use assets obtained in exchange for lease obligations	$3.1M	$0
Financing costs associated with the sale of common stock included in accounts payable and accrued expenses	$127.0K	$563.0K
Unrealized gain on available-for-sale securities	$19.0K	$99.0K
Issuance of pre-funded warrants in connection with the acquisition of in-process research and development	$177.4M	$0

Compare Vor Biopharma Inc. with another company

Leadership

Who has led Vor Biopharma Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Jean-Paul Kress2025–now

President

Robert Ang2021–now

Chief financial officer

2025

Chief executive officerJean-Paul Kress Jun 27, 2025 to now¹⁰
Chief executive officerRobert Ang Feb 4, 2021 to Jun 27, 2025¹¹
ChairJean-Paul Kress Jun 27, 2025 to now¹⁰
PresidentRobert Ang Feb 4, 2021 to now¹¹
Chief financial officerSandesh Mahatme Jul 10, 2025 to now¹²
Chief financial officerHan Wook Choi Oct 2, 2024 to Jul 10, 2025¹³
Chief financial officerNathan D. Jorgensen Feb 4, 2021 to May 7, 2024¹⁴

Board members and other officers (23)

Chief Medical OfficerJeremy Brett Sokolove Apr 9, 2026 to now¹⁵
Chief Development OfficerQing Che Zuraw Jul 30, 2025 to now¹⁶
Vice President of FinanceAmy Quinlan Jun 26, 2024 to Nov 8, 2024¹⁷
Chief Medical OfficerEyal C. Attar Oct 12, 2022 to Feb 18, 2025¹⁸
Chief Medical OfficerChristopher Slapak Feb 4, 2021 to Feb 3, 2022¹⁹
Chief Technology OfficerSadik Kassim Feb 4, 2021 to Feb 4, 2021²⁰
Chief Scientific OfficerTirtha Chakraborty Feb 4, 2021 to now²¹
Board memberDavid Zaccardelli Jul 9, 2026 to now²²
Board memberErez Kalir Jan 8, 2025 to now²³
Board memberAlexander Cumbo Jul 18, 2025 to now²⁴
Board memberMichel Detheux Jul 18, 2025 to now²⁵
Board memberSarah Burgess Reed Sep 8, 2025 to now²⁶
Board memberAndrew David Levin Dec 19, 2025 to now²⁷
Board memberWouter Joustra Dec 19, 2025 to now²⁸
Board memberFouad Namouni May 2, 2024 to now²⁹
Board memberDaniella Beckman Feb 4, 2021 to now³⁰
Board memberDavid Charles Lubner Feb 4, 2021 to now³¹
Board memberJoshua Resnick Feb 4, 2021 to now³²
Board memberKush Parmar Feb 4, 2021 to Jun 16, 2022³³
Board memberPeter Kolchinsky Feb 4, 2021 to now³⁴
Board memberRajeev M. Shah Feb 4, 2021 to now³⁴
Board memberRobert Ang Feb 4, 2021 to now¹¹
Board memberSven Ante Lundberg Feb 4, 2021 to now³⁵

Timeline

Jun 27, 2025New chief executive Jean-Paul Kress becomes CEO¹⁰
Feb 4, 2021New chief executive Robert Ang becomes CEO¹¹

Filings

398 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 46 major events, 182 insider forms, 65 large holders, 84 other. The latest 20:

Oct 5, 20264 EDGAR
Sep 4, 2026S-3ASR EDGAR
Aug 26, 20264 EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 14, 2026SCHEDULE 13G/A EDGAR
Aug 13, 2026SCHEDULE 13G/A EDGAR
Aug 11, 202610-Q EDGAR
Aug 7, 2026SCHEDULE 13G/A EDGAR
Aug 6, 2026SCHEDULE 13G EDGAR
Jul 30, 2026SCHEDULE 13G EDGAR
Jul 21, 2026SCHEDULE 13D/A EDGAR
Jul 21, 20264 EDGAR
Jul 9, 20263 EDGAR
Jul 9, 20264 EDGAR
Jul 7, 20268-K EDGAR
Jun 12, 20264 EDGAR
Jun 12, 20264 EDGAR
Jun 12, 20264 EDGAR
Jun 12, 20264 EDGAR
Jun 12, 20264 EDGAR

The 398 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 65 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
TCG Crossover Management, LLC	5,673,078	$104.4M	2.5%	No change
Fmr LLC	4,932,149	$90.8M	0.0%	+3,392,479
Fcpm III Services B.v.	4,117,354	$75.8M	10.1%	No change
BlackRock, Inc.	3,468,107	$63.8M	0.0%	+2,673,348
Venrock Adviser, LLC	3,041,719	$56.0M	1.7%	No change
State Street Corp	2,616,336	$48.2M	0.0%	+1,497,878
Frazier Life Sciences Management, L.P.	2,543,939	$46.8M	1.0%	No change
Ra Capital Management, L.P.	2,402,095	$44.2M	0.4%	−3,002,903
Vanguard Capital Management LLC	2,084,328	$38.4M	0.0%	+651,048
Caligan Partners LP	1,925,066	$35.4M	1.7%	No change
Paradigm Biocapital Advisors LP	1,750,000	$32.2M	0.6%	No change
Great Point Partners LLC	1,700,000	$31.3M	7.4%	−50,000
Nantahala Capital Management, LLC	1,690,000	$31.1M	0.9%	New
Geode Capital Management, LLC	1,062,469	$19.6M	0.0%	+719,896
NEXTBio Capital Management LP	889,164	$16.4M	7.5%	−110,803
ADAR1 Capital Management, LLC	680,626	$12.5M	0.6%	New
Logos Global Management LP	650,000	$12.0M	0.5%	−100,000
Rosalind Advisors, Inc.	648,600	$11.9M	4.5%	−51,400
Nan Fung Trinity (hk) Ltd	646,550	$11.9M	1.2%	New
Braidwell LP	573,104	$10.6M	0.4%	+106,330
Boothbay Fund Management, LLC	558,702	$10.3M	0.2%	+3,000
UBS Group AG	493,278	$9.1M	0.0%	+4,910
Millennium Management LLC	428,067	$7.9M	0.0%	+169,480
Sphera Funds Management Ltd.	416,417	$7.7M	1.1%	+94,500
Woodline Partners LP	379,723	$7.0M	0.0%	New

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARVor Biopharma Inc. filings on SEC EDGAR
2
SEC EDGARVor Biopharma Inc. filings on SEC EDGAR
3
SEC EDGARVor Biopharma Inc. 10-K for fiscal 2020
4
SEC EDGARVor Biopharma Inc. 10-K for fiscal 2021
5
SEC EDGARVor Biopharma Inc. 10-K for fiscal 2022
6
SEC EDGARVor Biopharma Inc. 10-K for fiscal 2023
7
SEC EDGARVor Biopharma Inc. 10-K for fiscal 2024
8
SEC EDGARVor Biopharma Inc. 10-Q for fiscal 2026
9
SEC EDGARVor Biopharma Inc. 10-Q for fiscal 2026
10
SEC EDGARJean-Paul Kress, Chief executive officer
11
SEC EDGARRobert Ang, Chief executive officer
12
SEC EDGARSandesh Mahatme, Chief financial officer
13
SEC EDGARHan Wook Choi, Chief financial officer
14
SEC EDGARNathan D. Jorgensen, Chief financial officer
15
SEC EDGARJeremy Brett Sokolove, Chief Medical Officer
16
SEC EDGARQing Che Zuraw, Chief Development Officer
17
SEC EDGARAmy Quinlan, Vice President of Finance
18
SEC EDGAREyal C. Attar, Chief Medical Officer
19
SEC EDGARChristopher Slapak, Chief Medical Officer
20
SEC EDGARSadik Kassim, Chief Technology Officer
21
SEC EDGARTirtha Chakraborty, Chief Scientific Officer
22
SEC EDGARDavid Zaccardelli, Board member
23
SEC EDGARErez Kalir, Board member
24
SEC EDGARAlexander Cumbo, Board member
25
SEC EDGARMichel Detheux, Board member
26
SEC EDGARSarah Burgess Reed, Board member
27
SEC EDGARAndrew David Levin, Board member
28
SEC EDGARWouter Joustra, Board member
29
SEC EDGARFouad Namouni, Board member
30
SEC EDGARDaniella Beckman, Board member
31
SEC EDGARDavid Charles Lubner, Board member
32
SEC EDGARJoshua Resnick, Board member
33
SEC EDGARKush Parmar, Board member
34
SEC EDGARPeter Kolchinsky, Board member
35
SEC EDGARSven Ante Lundberg, Board member